$9.50
▲ +$0.19
(+2.04%)
Vol 538K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.5B
ROE
-28.7%
Margin
-4366.8%
D/E
0.00
Beta
0.60
52W
$5–$33
Wall Street Consensus
12 analysts · Apr 20262
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
83.3%
Buy Rating
Price Chart
Similar Stocks
KYTX
Kyverna Therapeutics Inc
$537.0M
EIKN
Eikon Therapeutics Inc
CBIO
Crescent Biopharma Inc
$164.8M
ZURA
Zura Bio Ltd
$340.7M
RIGL
Rigel Pharmaceuticals Inc
P/E 6.9
$777.4M
LRMR
Larimar Therapeutics Inc
$326.1M
TRDA
Entrada Therapeutics Inc
$392.9M
VSTM
Verastem Inc
$581.5M
LYEL
Lyell Immunopharma Inc
$653.9M
Earnings
Beat rate: 20.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.71 | $-0.79 | $-0.08 |
| Sep 2025 | $-0.79 | $-0.63 | +$0.16 |
| Jun 2025 | $-0.62 | $-0.74 | $-0.12 |
| Mar 2025 | $-0.49 | $-0.51 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $607K | $613K | $566K | $937K | $683K |
| Net Income | -$16.0M | -$21.2M | -$27.3M | -$40.0M | -$33.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -27.1% | -27.1% | -27.1% | -27.1% | -28.7% | -28.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -4265.3% | -3836.6% | -3836.6% | -3836.6% | -4366.8% | -4366.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 38.27 | 38.27 | 38.27 | 38.27 | 32.67 | 32.67 |
Key Ratios
ROA (TTM)
-27.9%
P/S (TTM)
524.17
P/B
1.9
EPS (TTM)
$-2.29
52W High
$33.00
52W Low
$5.14
$5.14
52-Week Range
$33.00
Financial Health
Free Cash Flow
-$22.3M
Net Debt
-$70.7M
Cash
$72.2M
Total Debt
$1.4M
As of Sep 30, 2025
How does UPB compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
UPB valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
524.2
▲
3979%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.9
▼
24%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
UPB profitability vs Biotechnology peers
ROE
-28.7%
▲
57%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-4366.8%
▼
1423%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-27.9%
▲
40%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
UPB financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
32.7
▲
636%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.6
▼
38%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
UPB fundamentals radar
UPB
Peer median
Industry
UPB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio